Clinical Trial

Effects of Exogenous Ketosis on Proteinuria and Renal Function

Study acronym: KETO-CKD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 10, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
A randomized, placebo-controlled, double-blinded crossover study will be conducted. Fourteen patients with polycystic kidney disease (PKD) and 29 patients with proteinuric kidney disease will receive ketone bodies (Ketone-IQ) and placebo in a randomized order. Each treatment period is four weeks. There will be a wash-out period of two weeks in between treatment periods. Effect variables will be measured in the last day of each treatment period.
Trial Details
NCT Number NCT06867471
Lead Sponsor Gødstrup Hospital
Conditions Renal Insufficiency, Chronic, Polycystic Kidney Diseases, Proteinuria, Ketosis
Enrollment 43 participants
Start Date 2024-09-11
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-10